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Abstract: ABSTRACT
Background
There is a growing interest in aggregating more biomedical and patient data into large
health data sets for research and public benefits. However, collecting and processing
patient data raises new ethical issues regarding patient's rights, social justice and trust
in public institutions. The aim of this empirical study is to gain an in-depth
understanding of the awareness of possible ethical risks and corresponding obligations
among those who are involved in projects using patient data, i.e. healthcare
professionals, regulators and policy makers.
Methods
We used a qualitative design to examine Swiss healthcare stakeholders' experiences
and perceptions of ethical challenges with regard to patient data in real-life settings
where clinical registries are sponsored, created and/or used. A semi-structured
interview was carried out with 22 participants (11 physicians, 7 policy-makers, 4 ethical
committee members) between July 2014 and January 2015.  The interviews were
audio-recorded, transcribed, coded and analysed using a thematic method derived
from Grounded Theory.
Results
All interviewees were concerned as a matter of priority with the needs of legal and
operating norms for the collection and use of data, whereas less interest was shown in
issues regarding patient agency, the need for reciprocity, and shared governance in
the management and use of clinical registries' patient data. This observed asymmetry
highlights a possible tension between public and research interests on the one hand,
and the recognition of patients' rights and citizens' involvement on the other.
Conclusions
The advocation of further health-related data sharing on the grounds of research and
public interest, without due regard for the perspective of patients and donors, could run
the risk of fostering distrust towards healthcare data collections. Ultimately, this could
diminish the expected social benefits. However, rather than setting patient rights
against public interest, new ethical approaches could strengthen both concurrently. On
a normative level, this study thus provides material from which to develop further
ethical reflection towards a more integrative approach involving patients and citizens in
the governance of their health-related big data.
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ABSTRACT  
Background 
There is a growing interest in aggregating more biomedical and patient data into large health data sets 
for research and public benefits. However, collecting and processing patient data raises new ethical 
issues regarding patient’s rights, social justice and trust in public institutions. The aim of this empirical 
study is to gain an in-depth understanding of the awareness of possible ethical risks and corresponding 
obligations among those who are involved in projects using patient data, i.e. healthcare professionals, 
regulators and policy makers. 
Methods 
We used a qualitative design to examine Swiss healthcare stakeholders’ experiences and perceptions 
of ethical challenges with regard to patient data in real-life settings where clinical registries are 
sponsored, created and/or used. A semi-structured interview was carried out with 22 participants (11 
physicians, 7 policy-makers, 4 ethical committee members) between July 2014 and January 2015.  The 
interviews were audio-recorded, transcribed, coded and analysed using a thematic method derived 
from Grounded Theory.  
Results 
All interviewees were concerned as a matter of priority with the needs of legal and operating norms 
for the collection and use of data, whereas less interest was shown in issues regarding patient agency, 
the need for reciprocity, and shared governance in the management and use of clinical registries’ 
patient data. This observed asymmetry highlights a possible tension between public and research 
interests on the one hand, and the recognition of patients’ rights and citizens’ involvement on the 
other. 
Conclusions 
The advocation of further health-related data sharing on the grounds of research and public interest, 
without due regard for the perspective of patients and donors, could run the risk of fostering distrust 
towards healthcare data collections. Ultimately, this could diminish the expected social benefits. 
However, rather than setting patient rights against public interest, new ethical approaches could 
strengthen both concurrently. On a normative level, this study thus provides material from which to 
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 3 
develop further ethical reflection towards a more cooperative approach involving patients and citizens 
in the governance of their health-related big data. 
 
KEY WORDS 
Agency. Ethics. Healthcare stakeholders. Health data. Justice. Patient rights. Reciprocity. Clinical registries. 
 
BACKGROUND  
Patients’ healthcare data is used by a range of stakeholders, for a variety of different purposes, and this 
picture is rapidly changing. Greater digital integration of large health datasets is advocated for its 
benefits to clinical research and healthcare practice, blurring the distinction between research activities 
and medical care. [1] The expected social benefits are estimated to be considerable, especially with 
genomics and precision medicine aiming at more targeted and safer treatment for patients. 
Consequently, new approaches to informed consent are being examined, to facilitate the collection and 
use of routine patient data into big health data networks. Indeed, it is unrealistic to obtain informed 
consent for secondary uses of patient data, when the purposes of such uses are not known at the time 
of data collection. [2] As a result, patients’ rights to be informed and to give consent before their data 
is shared may not be respected, infringing upon the fundamental human right to privacy. However, 
patients also have increasing access to medical information, and could thus take on a more active role 
regarding their health-related data, based on their patient rights not only to privacy, but also to agency 
and participation.  
 
As the healthcare system relies increasingly on digital solutions [3], the rapid development of large 
patient data sets could have serious repercussions for individual patient rights, social group protection, 
and trust in physicians and public institutions. [4] It seems that many patients are unaware of possible 
conflicts of interest regarding data sharing, including for commercial purposes, and existing protective 
laws and ethical arguments do not fully address these new challenges. [5] New approaches to the 
ethical governance of patient data need to be envisioned and discussed. A first step would be to better 
understand the current ethical awareness of healthcare stakeholders (HCS) who contribute to the 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 4 
establishment of large patient data sets. Therefore, we have chosen to investigate empirically HCSs’ 
experiences and ethical consciousness, with regard to patient data, in the setting of clinical registries in 
Switzerland. 
 
Clinical registries (CRG) are a good proxy for large patient data sets. They use observational methods 
to gather patient data in order to assess medical outcomes and processes at population levels. [6] They 
cover a large healthcare domain, extending from clinical quality improvement, safety monitoring and 
cohort studies, to clinical research and policy evaluation, and they are confronted with similar digital 
changes and challenges as those of the wider field of patient healthcare data. There is growing concern 
for patient rights, as it could be possible to re-identify specific individuals, when CRGs built with de-
identified or anonymised data are linked, or include genetic information. There is also concern that 
aggregated information could stigmatize and harm some groups of patients and citizens, because of 
their disease, lifestyle or extra healthcare costs. HCSs should therefore be aware of their moral 
obligations when they decide to create or contribute to a clinical registry. 
 
Switzerland is a country with robust privacy rights written in its Constitution “Everyone has the right 
to be protected against the misuse of their personal data”. [7] Healthcare data are considered as 
sensitive personal data. To collect and use them, it is necessary either to have a legal basis, to 
demonstrate a dominating public interest, to have informed consent, or to have anonymous or coded 
data. [8] In comparison to other countries such as the United Kingdom, Australia, Sweden or 
Denmark, CRGs are not extensively developed in Switzerland. [9] However, this is changing. The 
Health2020 report gives an overview of health-policy priorities in Switzerland for the next 8 years. It 
identifies four interdependent priorities to be developed incrementally: Quality of life, equality of 
opportunity, quality of care provision, and transparency. In short, better data is required to transform 
the healthcare system into one with increased efficiency and improved quality, whilst containing 
growing costs. [10] Therefore, initiatives in favour of e-health, database linkage and national data 
sharing are facilitating the collection and use of routine patient data, and consequently the 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 5 
development of CRGs. However, to date, there is no empirical data on HCSs real-life experiences of 
CRGs.  
 
This paper reports a qualitative study designed to investigate HCSs’ ethical awareness regarding the 
management of patient data in Swiss real-life settings where CRGs are decided, created, managed and 
used. Whilst the literature reports an increasing involvement of patients with their personal data, the 
Swiss respondents did not seem to consider patient rights evolving into self-legislation and 
participation. Rather, scientific and legal matters seem to be their primary concern, regarding the 
creation and use of large patient data sets. This finding acknowledges the emergence of a tension 
between public biomedical research interests and patient rights regarding the newly emerging 
production and use of patient data. The study thereby motivates further normative reflections on the 
ethical approach that is taken for building large patient data sets, i.e. an approach that emphasizes a 
fair distribution of benefits and burdens amongst all stakeholders, patients and citizens included.  
 
METHODS  
A thematic analysis, derived from Grounded Theory, and using semi-structured interviews, was 
selected to explore HCSs’ individual experience and reflections. [11] The cantonal research ethics 
committee declared the study to bear no ethical risk (KEK-StV-Nr. 42/14). Participant information 
sheets were sent in advance by email to all possible interviewees. At the beginning of the interviews, 
consent forms and confidentiality agreements were explained, signed and exchanged.  
In order to have a wide diversity of roles and experiences, a purposive sampling frame selected three 
targeted groups of HCSs:  
- Group (M) comprises physicians involved in “Making” CRGs. Including two sub-groups, 
frontline physicians collecting data (sub-group M’) and data centre managers (sub-group M’’); 
- Group (R) includes people “Reviewing” CRG protocols in research ethical committees;  
- Group (A) includes people “Asking” for CRGs i.e. sponsors, regulators and policy-makers who 
require, fund or control the creation of CRGs.  
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The study sample did not include CRG patients, as their identities were anonymous or coded, i.e. not 
accessible. Thus, the abbreviation HCS used for respondents does not include patients. Recruitment 
was based on the information provided by the Swiss Medical Association “FMH” platform for CRGs 
[12], through the first author’s direct contacts and by snowballing. Sample size was determined by 
data saturation, i.e. the point at which additional data fails to generate new information. A range of 15 
to 25 interviews was foreseen, with group M expected to be the largest group, as its members are the 
closest to patients. 
 
Documents to participants were produced in 3 languages: French, English and German. The 
participant information sheet included a definition of clinical registries based on the U.S. Agency for 
Healthcare Research and Quality (AHRQ) document. At the time of the interview, this definition was 
read and the interviewees were asked to fill in a matrix, based on the AHRQ definition, to identify 
their own CRG experience. An additional file shows this in more detail [see Additional file 1]. 
 
The interview topic guide was developed with the help of an ad-hoc literature review identifying an 
initial framework of possible ethical issues to be raised by CRG stakeholders. An additional file shows 
this in more detail [see Additional file 2]. The topic guide included three items: 
- Participants’ personal experience of CRG. Assessed with open-ended questions;  
- General CRG issues. Interviewees were encouraged to think aloud. Prompt cards were used to 
highlight potential ethical issues and blank cards were used to record other emerging issues; 
- Possible recommendations for future CRGs.  
The topic guide was reviewed by external experts in qualitative research and epidemiology, and tested 
with native-speakers of the three languages. Prompt cards were used to facilitate discussion and 
communication with stakeholders who may not be at ease expressing themselves within the lexical 
field pertaining to ethics. Where possible, interviewees were asked to sort these cards by relevance to 
further assess their attitudes and beliefs. An additional file shows an example of the topic guide used 
for group M [see Additional file 3]. For groups R and A, the first item was slightly modified, so as to 
be more appropriate to these participants’ roles and experiences. To ensure a relaxed and trusting 
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 7 
atmosphere, a methodology of face-to-face interviews, at the interviewees’ location, was chosen. 
Interview proceedings were recorded in a qualitative research journal. 
 
Interviews were conducted by one of the authors (CMD), who is trained in qualitative methods. 
Interviews took place between July 2014 and January 2015, and were conducted in English, French 
and German. Thirty candidates were contacted, 22 accepted to participate. Reasons provided by those 
who declined participation, included lack of time (n=5) and a lack of experience with clinical 
registries (n=3 who then provided the name of a more appropriate candidate). Saturation was 
recognised after the first 15 interviews, however the study continued as 4 more interviews had already 
been planned. To confirm saturation, three more interviewees, from fields outside of the initial 
sampling frame (quality management, patient association, clinical ethicist) were selected using a 
discriminative sampling approach, and interviewed. The interviews lasted on average 59 minutes 
(median 60 minutes).  All interviews were audio-recorded and transcribed verbatim. The transcription 
was done on a continuous basis and data were exported into NVivoTM software for Mac. Coding and 
categorisation processes were gradually updated. First-level codes were regrouped in an iterative 
process between data collection and analysis. Memos were written throughout the research process.  
The first six interviews were used for developing the coding book. Additional coding was added when 
necessary with later interviews, and previous interviews were reviewed accordingly to ensure 
consistent coding for all transcriptions. Facilitated by NVivoTM, the thematic analysis procedure used 
successive matrices to cross-tabulate different categories of response. Our interpretation followed a 
mix of deductive (initial framework-informed) and inductive (theory-generating) approaches, with a 
continuous comparison method to interpret expected and emergent themes. [13] The final analysis 
followed the OSOP method [14], resulting in a map of key themes.  This contained explanations of 
patterns and linkages, analysis of deviant cases, and allowed us to generate inputs for an emergent 
theory. 
 
The first author coded all the transcripts, developed themes and proposed the final analysis. To finalize 
the coding book, colleagues, acknowledged at the end of the article, independently coded a sample of 
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 8 
de-identified transcripts in English, French and German. As educational background can influence 
qualitative interpretation, it is important to note that the first author has a medical background and 
further education in bioethics and empirical research. The co-authors, who enriched and validated the 
analysis, have backgrounds in biomedical ethics, philosophy and medicine. 
 
RESULTS  
Respondent characteristics 
Table 1 shows the participants’ demographic information. Health domains were diversified. The 
region of Zurich and the public health sector were the most represented. A majority of interviewees 
were male and had a medical background. Most of the interviewees had experience in more than one 
type of CRG. A few interviewees (mainly sub-group M’) did not find it relevant to differentiate 
between CRGs for research and CRGs for quality improvement, as for them, these different goals 
require the same data, and indeed, the patients involved are the same. 
 
Categories and gradual findings 
Five anticipated categories, identified in the initial framework of expected ethical issues, where used 
as prompt cards:  
- patient information  
- data ownership 
- trust  
- moral obligations 
- confidentiality 
In the first interviews, additional issues arose concerning data set linkages, data interoperability, data 
sharing, communication between stakeholders, feedback of results, quality of data, utility of CRG, 
funding issues and legal constraints. In order to take into account these issues and to fully explore their 
ethical dimensions, two supplementary prompt cards were added after the first 6 interviews: 
- communication-networking  
- long-term value  
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Table 1. Characteristics of the interviewees (n=22) 
 
Male (n, %) 19 (86%) 
Age (median, range) 55 (39-68) 
Years of experience with clinical registries (median, range) 14 (1.5-27) 
Experience working abroad >1 year (n, %) 12 (55%) 
Number of registries currently involved in (median, range) 2 (1-6) 
Current main role regarding CRG (n) 
First line data collectors (M’) 
CRG manager (M’’) 
Initiators/ sponsors (politics, federal administration, patient organisation, quality 
management) 
Reviewers (cantonal ethics committee, clinical ethicist) 
 
6 
5 
7 
 
4 
Education background (n)* 
Medical doctor 
PhD science 
Economy 
Law & humanities 
Nurse 
 
16 
5 
1 
2 
1 
Health care domain (n) 
Main Medical fields 
Anaesthetics 
Cardiology 
Dermatology 
General practice 
Infectious diseases 
Nephrology 
Paediatrics 
Public Health 
Other HC fields  
Data management direction 
Quality management 
Health administration 
Ethics 
Health policy 
 
 
1 
1 
1 
1 
1 
1 
1 
2 
 
2 
1 
3 
4 
3 
First language (n)* 
German 
French 
Italian 
 
17 
6 
2 
Places of work (n) 
Geneva 
Lausanne 
Fribourg 
Bern 
Zürich 
 
1 
3 
2 
4 
12 
Sector (n) 
Public 
Private 
 
19 
3 
 
* Interviewees could satisfy 2 characteristics. CRG: clinical registries  
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Categorising was based on these seven prompt cards, and completed by the following emergent 
categories: perceived CRG definition and knowledge, legal aspects, transparency, governance, 
beneficence, similarities with biobank, empathy with patients, and a parking-lot category named 
“other possible ethical issues”, which included elements of card strategy and prioritization.  
 
Thematic analysis 
The data was very rich. Comparing and looking for interactions across categories in the light of the 
research question on HCSs’ ethical awareness, the analysis identified three broader themes: 
Respondent behaviour, attitude and strategy. Behaviour described how HCSs worked or could act in 
the context of the production and use of the CRGs. The theme attitude revealed HCSs’ thoughts, 
beliefs and values towards themselves, peers, patients, and society, i.e. disclosed something about their 
moral obligations. Strategy exposed respondents’ reactions when confronted with a tension between 
their actions and their beliefs. 
 
Respondent behaviour 
All interviewees emphasized the need to intervene in CRG management with strong legal and 
operational rules. Legal concerns were extensively discussed, despite the absence of specifically 
legally oriented questions in the topic guide. (Table 2) Swiss law confers upon HCSs the right to 
record and use CRG data. It assures that HCSs respect privacy rights, confidentiality, anonymity-
coding rules and informed consent. In effect, this judicial backbone strengthens professional 
deontological rules requiring that HCSs first do no harm and abide by their professional secrecy duty. 
 
 Depending on the type of CRG as identified in the additional file 1 [see Additional file 1], legal 
requirements are different regarding data protection, confidentiality, patient consent and ethical 
review. When CRGs were legally mandatory for healthcare statistics, the respondents considered them 
as good examples of CRGs with an underlying stable structure and stable financial basis. Additional 
ad-hoc research purposes could thus be managed by simply adding other predefined items into the 
case report forms of the initial registry. Regarding non-mandatory CRGs, the interviewees were 
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fighting for a legal basis for opt-out consent procedures, rather than an insistence upon opt-in consent, 
to facilitate CRG recruitment. Some HCSs mentioned their discretionary power in addressing 
confidentiality or informed consent issues depending on the types of patients included.  For instance, 
the HIV registry was managed with a high level of confidentiality due to the risk of discrimination, 
whereas in the mandatory Swiss Transplant Cohort patients’ confidentiality was not a major issue due 
to the transparent transplantation context. 
 
Major concerns pertained to the difficult distinction between clinical care and research CRGs. 
According to current regulation, only research CRGs need to be reviewed by the corresponding 
Regional Research Ethical Committee. In practice, the question raised by respondents was whether 
they should submit certain CRG projects to the research ethical committee. Indeed, their classification 
as research projects depends on the interpretation of the Swiss Human Research Act (HRA), as 
illustrated in the following examples:    
 research CRGs with anonymous or coded data,  
 quality CRGs delivering generalizable output,  
 CRGs including “de-identified” biomarkers and genomics data,  
 and all secondary uses of CRG collected data for research projects that were still unknown at 
the time of patient recruitment.   
 
Confronted with this issue, HCSs behaved differently. Many viewed the obligation for a written 
informed consent, as too burdensome. Group M defined research based on the purpose and use of the 
CRG. In contrast, participants from groups A and R preferred to classify CRGs with non-identifiable 
data as monitoring tools, and not as research, stating that they could subsequently correct their 
approach with a retrospective ethical authorization if CRG results were published as research.  
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Table 2: Healthcare professionals’ behaviour – Legal norms 
Necessity of legal norms:  Interviewee comments (A, M’, M’’, R indicate group affiliation) 
 
For opt-out preferential option 
 
 
 
 
 
 
 
 
 
As a basis for confidentiality 
 
 
 
 
 
To better define research  
 
 
 
 
 
With guidance for implementation 
 
 
 
Applied with an idea of prudence 
 
 
 
 
[Sub-group M’’]. “First of all we had to fight for the legal fundaments, 
because if you don’t have a legal fundament then in cantons some hospitals 
would simply refuse to deliver the data, which would then lower our response 
rate below the international acceptable limit. So, legal, a legal baseline is very 
important…There is a moral obligation to use data, to improve quality of life 
of patients, therefore to have good quality data and completeness. It means 
obligation to have an opt-out...There is a conflict of moral obligation with the 
data protection officer who wants first to protect individual privacy. That is 
why a law will help for [name of the clinical registry] registry.” 
 
[ Sub-group M’]: “Confidentiality is very important to get that your patient 
information is given and that the patient is not disappointed. Depends on what 
you do, I mean, organ transplant recipients everybody knows they are 
transplanted so there is not that much to hide. With HIV that’s much different. 
You have more concern in the HIV cohort study.” 
 
[R] [translation] “There is a clear contradiction in the definition of a clinical 
trial in the law and in the ruling order. As a result, researchers want to take 
advantage of this…we have recurring discussions on this question, whether it 
is research or not. And researchers put a lot of energy and intellectual efforts 
to argue that in this particular concrete case, it is not research.” 
 
[Sub-group M’’] “Well I mean, there is the legislation and so on, but maybe 
there is probably not enough guidance in practice, that is known by the people 
who are developing registries and using them.” 
 
[Sub-group M’] “That’s an ongoing discussion. Because it’s a pain. …  if you 
have a question that is beyond an individual patient’s treatment, basically it’s 
science. … So my interpretation is that we have to ask for every project for 
specific approval for the specific question, which is what I am doing...but not 
everybody in the cohort study is of my opinion and we have heated discussions 
because it makes a big difference if you have 40 projects running in this 
cohort study which are scientifically looking at the cohort study and all these 
40 need ethical approval or don’t. … you can go through any kind of audit 
and I know if you don’t have ethical permits you are lost. You are dead before 
the game even starts; because for a lawyer, if you have no document, you’re 
dead.” 
 
Besides these legal aspects, interviewees’ behaviour focused on the operational management of the 
CRGs, i.e. data quality, standardization and completeness, system interoperability, and financial 
conditions. (Table 3) Interviewees pointed out the risks of collecting the wrong data, or in the wrong 
way and generating waste (“data cemeteries”). The prospect of not using CRG information was 
considered as bad as misusing it. The further that interviewees were from the data collection process, 
the stronger was their doubt about CRG quality and value. All interviewees insisted on the necessity of 
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working with a steering committee that would set the rules of good clinical practice, data access and 
research authorship. 
 
Table 3: Healthcare professionals’ behaviour – Operational rules 
Good operational management  Interviewee comments (A, M’, M’’, R indicate group affiliation) 
 
Importance of data quality 
 
 
 
 
 
 
Trust in quality 
 
 
 
 
 
Good management needs human 
and financial resources 
 
 
 
 
Issue of definition of quality  
 
 
 
 
 
 
Steering committee to set the rules 
 
 
 
 
 
Utility is essential 
[Sub-group M’, principal investigator]: “The crucial aspect of a registry is what 
kind of data do you put into this registry, and how well is this data controlled, 
and how good is the quality of this data in the end.  This is what really counts… 
It is difficult you know; I'm continuously involved if there are some questions 
about definitions. Definitions always evolve. How do you, what kind of data point 
do you collect?” 
 
[A]: “My special problems with the evaluation registries as we call them, is that 
the physicians deliver the data to these registries, enough data, good quality data 
and that you have registries that you can use! That was always a problem and it 
is a problem: how to make them mandatory or how you can guarantee that the 
data are full and good. That is always the problem.” 
 
[R]: [translation] “Money is necessary, for infrastructure and people, but public 
services are always reluctant. …With the National Research Fund, it is 
discouraging, they don’t want to engage themselves in the long term…a better 
coordination should exist between institutions and the National Research Fund, 
with a guarantee at the launch of a project that institutions will take over later.” 
 
[Sub-group M’]: [translation] “It is difficult to measure quality in medicine. What 
is it? Is it patient satisfaction? Is it cost-effectiveness? Because when 
parliamentarians speak about quality, it is completely wrong: for them, it is 
quality – price ratio; when they think quality, it is profitability, and for me it is 
not. Quality has nothing to do with money…because if you want true quality, it 
would be expensive.” 
 
[Sub-group M’]: “You need some clear rules how will these data and samples be 
used, you know, by whom? And we have actually modelled ourselves a bit along 
the HIV cohort study which has a scientific committee; so, whenever somebody 
has a research question, he has to go there, has to write the proposal, we review 
the proposal and we accept the proposal or not.”  
 
[Sub-group M’’]: “If we collect data, we have to organize everything that we can 
create as much information out of this data as possible. So, I think it is, it’s only 
serious to collect data if they can be used for something. If they are just collected 
and if they are not, cannot contribute to improve the system, then it is, I think it is 
not ethical to collect them.” 
 
Respondent attitude 
A majority of interviewees declined to comment on the card on moral obligations, touching and 
looking at the card, but then moving on to comment on another card instead. Some HCSs considered 
the word “moral” too judgemental or inappropriate, and refused the “outing” on moral obligations. 
Nevertheless, morally connoted words like “right” and “wrong” were frequently used when they 
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thought aloud about patient information, confidentiality, trust and long-term value. A few HCSs 
referred to moral obligations as the roof governing the whole CRG activity. Interviewees’ attitude 
varied between the different groups, based on their proximity to patients and the existing deontological 
code for physicians. 
 
i. Attitude towards themselves and other HCSs (Table 4) 
Group A said that moral obligations were implicitly handled in their political engagement when they 
were making laws. They recognized the moral obligation to apply legal norms, and to modify the 
legislation if necessary. Group M was aware of professional duties to inform patients, to respect 
secrecy, to accept peers’ scrutiny and finally to participate in CRGs as in other types of activities that 
would improve healthcare quality for patients. With regard to patient information, their motivation 
was not only deontological, but also utilitarian to maintain a trustful relationship for increasing patient 
participation in the registry and maintaining patients in a CRG cohort. A minority of interviewees 
considered that the addition of federal and local legislations on top of the professional code of 
deontology represented an excessive administrative burden. Most of the interviewees recognised that 
communication with external physicians, experts and politicians was difficult. One interviewee 
associated this communication with the word “preaching” in order to illustrate the effort required to 
convince others that the data are of good quality, representative, and provide real-life evidence, i.e. 
that people could trust the CRG results and apply them in their daily work. Group R considered the 
other HCSs as somewhat inept given their relatively poor legal and ethical knowledge, and a 
reluctance to share data. 
The issue of data sharing and networking was regularly mentioned but difficult to clarify with 
interviewees: On the one hand, they showed a willingness to harmonize definitions and standardise 
electronic entries to ensure the quality of the CRG.  On the other hand, they appeared reluctant to 
communicate with information technology specialists, who were considered insufficiently capable to 
understand and subsequently translate medical information into standardized items. Furthermore, 
some respondents recognized that transparency could be perceived as another obstacle to data sharing, 
because physicians may prefer non-transparency. Finally sharing CRG data was not synonymous with 
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linking registries to create bigger data sets. The interviewees close to patients insisted on the 
importance of meaningful information. They sought to provide bottom-up inputs to data centre 
managers and steering committees in order to help make the findings understandable and meaningful. 
For them, “big” was not clinically interpretable and useful for their practice.    
 
Table 4: Healthcare professionals’ attitude towards themselves and peers 
 
Attitudes Interviewee comments (A, M’, M’’, R indicate group affiliation) 
Moral obligations inherent to 
political engagement 
 
 
 
 
 
Necessity to better inform patients  
 
 
 
 
 
 
 
 
Norms can be burdensome 
 
 
 
 
 
 
 
 
Issue of transparency and 
communication 
[A] [translation] “They [mandatory hospital CRGs] are mandatory 
statistics, therefore it seems relatively obvious as moral obligations to 
maintain them.”  
 [A] “Our role is to propose to the parliament a law, that is useful, the 
most useful possible [for CRG].  That’s I think our most noble and our 
most important duty.” 
 
[Sub-group M’’]: “I think the patients are not well informed and I think 
maybe there are some fields, which could be destroyed if there would not 
be an objective information. You know, at the moment, there are a lot of 
news for example showing the data or pictures from persons are provided 
on the internet because they have been taken out of clouds or whatever. 
And I think this increases the fear, and I think it will be very important to 
inform patients on what data are stored, why they are stored and that they 
cannot be identified for example.” 
 
[Sub-group M’]: “We don’t need new regulation because as a doctor, as a 
lawyer, you have your professional obligations to keep your clients or 
patients’ data secret. So, if you don’t do that, you can be brought to court 
nowadays, so I don’t see what it changes if the patients must sign 5 such 
forms entering a hospital, on biobank, on whatever registry... it is 
counterproductive. You want to have an informed and empowered patient 
but it’s completely the other effect, you induce with paperwork. Nobody 
can understand the legislation.” 
 
[Sub-group M’’] “I am absolutely convinced that physicians do not want 
to have this level of transparency, because everyone in this country who is 
allowed by the patient to load, enter to his file, can see what the other 
physician did, and “untransparency” is a very important thing in the 
health care system.” 
 
 
ii. Attitude towards patients’ role and agency (Table 5) 
All interviewees recognized patient rights to know, to protect privacy and to own their data. However, 
their attitude regarding patient information indicated some discrepancies with this position. No clear 
answer was given to the question of the destiny of data following patient withdrawal. Also, the 
possible risk that patient information could be neglected in the absence of formal consent was 
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accepted – for instance, when a data centre treated their data anonymously, patients were not supposed 
to be informed.  
 
Table 5: Healthcare professionals’ attitude towards patients 
Perception of patients’ capacity Interviewee comments (A, M’, M’’, R indicate group affiliation) 
Patients want to know 
 
 
 
 
 
 
 
 
Patient information is not systematic 
 
 
 
Not much value assigned to patient’s 
capacity to understand  
 
 
 
 
 
 
 
 
Patient information is a moral duty 
 
 
 
 
Patient information is useful to 
maintain trust 
 
 
 
Patients have the capacity to contribute 
actively 
[A] [translation] “Patient information is the most important. Patients 
need information in order to be able to consent or refuse. Information 
should be in a language they could understand.”  
[M’’] “We have asked the physicians and the patients what they 
thought about that, and they were saying: well I am not against but I 
want to be informed, I want to be informed preferably by my family 
physician, by my GP and I want to know what is going on, but I am not 
opponent to this type of research, but I would like to know.”  
 
[Sub-group M’’] “We have a formal agreement [from the federal 
commission for professional secrecy] that the data can be transmitted 
to us. They are anonymous, and the patients don’t know.” 
 
[Sub-group M’] [translation] “Well, for me it is important to inform 
patients …yes the patients, even if they usually don’t care about it.”  
[A] [translation] [interviewer’s question about the perception of 
patient’s position] “The patient? it is eight million of citizens, and each 
of them have their head, their morality, their feelings, their perception 
of the reality… There is no patient lambda …If I had to answer your 
question, I would say that a patient lambda in Switzerland has no idea 
about what you are asking- It is a level of mental abstraction that is 
present in less than 1% of the population.” 
 
[Sub-group M’] “We do not need [an informed consent] because we, 
basically we collect data which is collected anyway, so you could argue 
the patient doesn't really care, but he needs to know what it's done, you 
know.” 
 
[Sub-group M’] “A well informed patient is convinced that he can 
really trust how his data is handled, about security of the data. He will 
be more willing to say yes; I agree that my data will be put into this 
database.” 
 
[Sub-group M’’] “We also plan to have a, in a second line, a patient 
self-registry, so that the patients themselves can register themselves 
into the registry. So, there is two ways to go in. So, either for the 
doctor, physician, or then for the patient himself: I have this rare 
disease, I want to be part of this registry.” 
 
Despite our research design including the prompt cards “patient information” and “trust”, respondents 
didn’t attach much importance to empathy with patients, patient information or patient agency; many 
interviewees thought that patients did not care about or could not understand CRGs. Exceptions to this 
attitude concerned one participant who belonged to a patient association in the discriminative 
sampling, as well as most of the treating physicians who – in comparison to other HCSs – indicated 
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greater concern for patient information in the interests of building and maintaining a trusting 
relationship with their patients.  No respondents were ready to accept patient membership in steering, 
nor they think that patients could act as members of a governance body. They never mentioned the 
possibility or need to empower patients’ agency. Some interviewees remarked that patient associations 
were weak and that patient participation in a steering committee would only be an “alibi” and have no 
added value. A few respondents stated that patients were too “self-centred” to be able to participate. 
Only one interviewee spoke about the possibility of patients registering themselves in a CRG, in the 
special context of rare diseases. 
 
iii. Attitude towards society (Table 6) 
A few interviewees explained that patients disliked the label “patient” as they were hoping for 
recovery to “normal”. They explained that patients would like to be part of the overall citizen 
community, i.e. the society. Respondents acknowledged CRGs’ societal value as the delivery of public 
benefits and the possibility of improving medical knowledge. They recognized that, depending on 
their purpose, all health stakeholders could benefit from CRGs. Physicians and hospitals would 
improve their work, researchers would identify new patterns, experts would make better-informed 
recommendations, public health players would justify their decisions and health regulations, and 
insurers might introduce premium rebates. As a result, patients in general would benefit from all of 
these improvements, i.e. patients’ family and future patients. Some interviewees mentioned that 
patients themselves might secure direct benefits as participants of longitudinal cohorts could benefit 
from better medical follow-up, as they are regularly contacted.  
 
For most of the respondents, CRG data sharing and the dissemination of this information increases the 
social value of CRGs. The belief in these public benefits justified public funding and governance. 
Group R was particularly supportive of moral obligations concerning transparency, openness and 
comparative effectiveness between HCSs. To this end, it was suggested that physicians needed to be 
better trained in information technologies and public health sciences. Group A focused as a matter of 
priority on addressing two major risks: privacy infringement because of excessive transparency, and 
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the waste of data because of data cemeteries and low cost-utility ratio. Perspectives of the waste of 
data were dependent on the political standpoint of policy-makers from group A. Those from the right 
and liberal political parties preferred to restrict public spending and emphasized the risk of waste of 
data. In contrast, the representatives from the political left were more open to take on a financial risk 
to develop long-term CRG research in order to measure and improve equity in access to care. It seems 
that conservative policymakers believe in public interest for patient data but do not equate this with 
public funding. 
 
Governance was an important issue, but subject to conflicting views. Most interviewees supported 
public governance to serve public interest. For them, CRG resource allocation should remain 
scientifically and academically driven and be free from conflicts of interest, as in the case for projects 
supported by the Swiss National Research Fund.  A few interviewees were in favour of small, non-
bureaucratic governance, independent from institutional, economic or political powers, i.e. public 
authorities would provide financial support, but would not be involved in CRG governance. For group 
R, governance was not the role of an ethical committee, but it required a common long-term political 
vision including the prioritization of CRG projects, and an ethics of responsibility for each physician 
and patient. 
 
The definition of “public” was restricted to institutions and public associations or academies. No 
interviewee considered representatives of civil society as potential members of governance 
organisations for CRGs. Nor did they support health data literacy programs to facilitate the 
participation of citizens, even when the question was directly asked. One interviewee said that the 
necessary education should be done in school and not later, because it would not be feasible or 
effective with patients or adult citizens. The role of communities and society was mainly limited to 
financing CRG via cantonal and federal contributions, and sometimes, unusual health contributors 
such as the national lottery. Moreover, lobbying or private funding were seen as risking unfair 
allocation of healthcare resources.  
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Table 6: Healthcare professionals’ attitude towards society 
Perception of society benefit & role Interviewee comments (A, M’, M’’, R indicate group affiliation) 
Patients are citizens 
 
Clinical registries benefit society 
 
 
Patients may benefit directly 
 
 
 
Social value is related to meaningful 
use 
 
 
 
 
 
 
Value increases with data sharing  
 
 
 
Value needs better physicians’ 
education  
 
 
 
 
 
 
 
Value includes financial risk-taking 
 
 
 
 
Value is related to trust 
 
 
 
 
 
 
Value and governance  
 
 
 
Conflicts in interest 
[A] “The patient is all of us”.  
 
[Sub-group M’] “Primarily it’s a tool for everybody who has a research 
question “.  
 
[Sub-group M’’]: “It is always known that patients in a registry, they are 
usually better followed than other patients. ...because we have to see them 
every half year [in the cohort].” 
 
[Sub-group M’]: “You want to do that in a meaningful way; I mean we 
don’t do it in a sense that the DRG system; all the patients get a DRG kind 
of diagnosis, you know. So, in the end of the year you can bring all these 
DRG diagnosis together.  But they are worth not that much.  Obviously, 
they are worth very much because you are paid according to the DRG so 
it's important, but in terms of what they really say, what the patient has, 
and as outcome, it's, it’s, you can't use it.” 
 
[R] “Sharing data increases the value of the collected clinical registry. A 
good register communicates, publishes results and invites further research 
proposals on these data.”  
 
[R] “Physicians should understand the value of what they do when they 
use epidemiological data. Most physicians feel the moral obligation to 
keep registries for good quality assurance, but they tend not to share them, 
not to be transparent. Therefore, comparison is not possible and quality 
could not be improved. We should have a better national medical 
education and training, including evidence based medicine, epidemiology 
and the practice of critical thinking and reflection. Continuous education 
as well for medical development.” 
 
[A] [translation] “There is always a risk of error in the long term. I have 
some colleagues who told us that investments have to be made only in 
research projects that we are sure in advance that they would provide 
results. They have a serious problem understanding the word research.” 
 
[A] [translation] “Here, the socialist party will say: we need a beautiful 
law that ensures financing, governance, and an interdisciplinary 
governance which controls everything…etc. and which costs three times 
more. What the right side says is: no, we provide a legal basis and let the 
people free, and if they make mistakes, there are enough means to address 
them …it is this vision that I called the principle of trust.” 
 
[Sub-group M’] “The CRGs should have a medical and social value. The 
Federal Office of Public Health is not apt to do it. It could financially 
support CRGs but only professional societies could govern CRG.”  
 
[A] “Transparency issue is a possible deceptive motivation for a registry. 
CRG may be advocated for patient interests, but in fact would be 
performed and used for publications and academic careers of the 
investigators first of all.”  
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Respondents’ suggested strategy  
When they came across moral conflicts between norms guiding their behaviour and their attitudes, 
interviewees started to develop practical strategies to support decision-making. All respondents 
wanted to improve the utility of the CRGs, i.e. applying norms to increase the number of included 
patients, stimulate physicians’ participation, improve data quality and interoperability, and align legal 
and ethical guidelines amongst CRG stakeholders. Nevertheless, when confronted with moral 
conflicts, there was no consensus on which specific strategies to adopt, as shown in the following 
examples:  
- Strategies towards enhanced patient recruitment were dependent on HCSs’ beliefs on the balance 
between patient rights and public interest. Sub-group M’ relied on better patient communication to 
develop more trustful relationships in order to include more patients. Sub-group M’’ believed in 
their capacity to influence policy-makers to promote opt-out forms of consent and new forms of 
consent. A few suggested using financial strategies either as incentives (pull strategy) or as 
penalties (push strategy) for investigators.  
- When confronted with the doubt about the distinction between care and research CRG, tensions 
were apparent and attitudes diverged. The majority chose the definition of a care CRG in order to 
avoid the administrative burden of a research ethical committee, this potentially at the expense of 
patient rights. Only a minority of HCSs implemented a default-strategy of systematic declaration 
to the research ethical committee. This latter attitude was also motivated by the desire to be 
protected from any legal risk due to infringement of the HRA.  
- Tensions were present regarding data ownership. All respondents considered patients as data 
owners, but only a minority of HCSs thought that patients ought to have some kind of 
compensation rights for the use of their data. Moreover, contrasting concepts were envisaged to 
facilitate the use of data. Group M favoured stewardship towards their patients’ data, whereas 
group A preferred a split “puzzle” approach to data ownership avoiding power concentration.  
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Final analysis and emergence of an initial theory 
The reflection on the former themes has led to a better understanding of HCSs’ ethical awareness. 
Figure 1 organised the themes on one sheet of paper (OSOP) which served as the basis for reflection 
to search for patterns, links, comparisons or oppositions, and explanations with the aim of establishing 
the story in each theme and developing perspectives for an all-inclusive final interpretation.  
 
Figure 1: Thematic organisation for in-depth understanding 
 
The qualitative interpretation supports the passage from a thematic description to an initial theory 
regarding the research question. The proposed theory about HCS’s ethical awareness was based on the 
following three interpretative perspectives:  
i. A perspective of professional needs and public interest. HCSs concentrate on legal norms, 
deontological code, operational data management rules and good clinical practice, in order to 
ensure the legitimacy and utility of the collection and use of patient data necessary for the 
different types of CRGs. Their ethical justification relies on the principles of non-maleficence and 
prudence as well as social utility and benefits. In contrast, they give little consideration for patient 
rights to be adequately informed, i.e. to be informed even when consent is not required, to receive 
feedback, to have the right to ask questions and the right “not to know”. HCSs argue that patients 
have no moral obligations to participate in CRGs, but at the same time they try to stimulate 
participation by calling for opt-out procedures and new forms of consent. HCSs’ ethical awareness 
seems to be more guided by their professional needs surrounding the collection and use of patient 
data than by an interest in the protection of patient’s rights and autonomy. From a normative point 
of view, this utilitarian perspective may impede an adequate assessment of the possibility of 
infringing patient rights for the sake of professional and public interests. 
ii. A limited perspective on transparency and trust between HCSs and with patients. Communication 
between HCSs is problematic and compromises peers’ trustworthiness, because they do not 
support unconditional transparency and scrutiny of their work, and show limited interest in 
bottom-up inputs. Communication with patients raises a similar issue.  HCSs do not assign much 
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value to the patients’ capacity to understand the complexity of the production and use of large 
patient data sets, and therefore do not foster reciprocal trust with patients. These limitations with 
transparency and trust increase the risk that peers are reduced to simple data collectors, and 
patients to simple data sources in the production of a CRG. These difficulties with recognizing 
patients as fully capable of shared decision-making indicate that HCSs’ interests for patient data 
could overcome the consideration of patients as an end themselves. The potential utilitarian bias in 
favour of research and public interests noted above is therefore insufficiently balanced by a more 
Kantian deontological approach forbidding the treatment of individuals merely as the means to 
others’ ends. 
iii. A perspective of governance by experts at the expense of citizen participation. HCSs have 
demonstrated little overall awareness of the role of citizens in the governance of CRG patient data 
and the need to develop citizens’ education for such a role. HCSs don’t foresee the involvement of 
civil society representatives in governance. They recognise the need for public funding, but not the 
possibility that society could contribute to assess the whole range of social benefits and risks, i.e. 
balancing privacy against public interests. From a normative perspective, the process of 
deliberation and decision-making thus remains unduly expert-centred, favouring research, 
economic and political objectives, with a risk of conflicts of interest, hidden agendas, and biased 
decisions regarding distributive justice. 
 
The resulting initial theory states that HCS could be more aware of the potential tension between 
patient rights and public interest around patient data. It is summarily represented with the scales of 
public interest vs patient rights on the left of Figure 1. This initial theory will be examined and 
enriched in the following section. 
 
DISCUSSION  
This exploratory qualitative research brought to light a potential tension between public interest and 
patient rights regarding patient data. Patients are solicited to give up rights to their health-related data, 
but their participation appears restricted to their role as data donors, with little recognition of the 
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possibility of meaningful participation in decision-making. This potential tension carries the risk of 
weakening trust in the patient-physician relationship, undermining solidarity and justice at the societal 
level, and unfairly infringing upon patient rights. Therefore, the transferability of these findings to 
other debates regarding the use of patient data in the healthcare system needs to be examined. 
 
No other qualitative study to date has explored the subject in Switzerland. However, our findings are 
in line with the current evolution of the Swiss healthcare system. First, the Federal Act for National 
Oncology Registry, approved in March 2016, will ease the production of patient registries with an opt-
out procedure. [15] Second, operational recommendations for health-related registries have been 
published in July 2016 to ensure data protection and data quality, appropriate information and 
management, and cost/utility of CRG data. [16] Finally, a broad informed consent for all secondary 
research usages of samples and related patient data has already been implemented in some public 
hospitals, and is on its way to be implemented nationally. [17] All these events were in discussion at 
the time of the interviews, and it is thus difficult to determine whether the events have influenced the 
interviewees or if the reverse is true. Nevertheless, there has not been a concomitant development of 
ethical considerations promoting patient agency and consumer participation in the management of 
patient data. Neither has the new national project of Swiss Health Personalized Network involved 
patients or donors in its governance. [18]. Furthermore, a Swiss parliamentary motion requiring a legal 
approach to ensure patient representation in the governance of biological data has recently been raised 
but rejected, confirming the pertinence of our findings in the current Swiss context. [19] 
 
Previously published literature confirms that healthcare professionals and administrators give little 
attention to patients’ ability to understand or contribute to governance. The qualitative studies referred 
to in the design stage of our study interview guide were conducted in the UK and North America. [20-
30] Similar to our findings, healthcare professionals and administrators in these studies were vigilant 
about data protection rules, data security, confidentiality, responsibilities for patient data, and they 
strived for simplicity in data processes, transparency, and consensual rules between peers. These 
studies also included focus groups or interviews with patients.  Yet, patients’ opinions showed some 
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divergence with other HCSs’ perceptions. Patients accepted the sharing of their data, but wanted to be 
informed and to have the freedom to participate or withdraw. They did not want their data passed to 
third parties, insurance or pharmaceutical companies, without being specifically asked beforehand. 
Patients usually favoured trust and partnership with their treating physicians. In fact, it seems that 
citizens in general, as well as patients in specific, have the capacity to intervene and assess the just 
equilibrium of patient rights and public interest concerning the use of personal health data. In 
Australia, a country with a long history of clinical registries, community and consumer representatives 
already participate in the governance of clinical registries. [31] More recently in the USA, following 
the Obama initiative on precision medicine, community citizens have participated in the registry 
design of the “one million Americans” cohort project. [32] Indeed, Fair Information Practices 
Principles (FIPPs) have been developed to set common standards for patient involvement in the 
governance of personal health and genomic data. [33] 
 
Assuming the transferability of our findings to all health-related big data, the tension between legal, 
professional and operating norms on the one side, and respect for patient agency and citizen 
contribution on the other side, could be difficult to resolve in the absence of additional ethical 
guidance. There is a risk that those with the expertise or economic power to effect change might 
favour additional legal and operational norms, to authorize the use of patient data for research and 
public interest. Thus, purported social benefits could justify ever-greater usage of patient data, at the 
expense of listening to patient voices. This could lead to an erosion of the necessary reciprocity, 
solidarity and trust in the healthcare system. Consequently, more data sharing, justified on the grounds 
of social benefits, could foster distrust towards healthcare professionals and the public healthcare 
system in general, thus reducing the expected social benefits.  
 
The identification of this potentially negative scenario is stimulating new ethical approaches. The 
World Medical Association (WMA) has thus raised concerns about the management of large patient 
data sets and biobanks, some relating to privacy, and others relating to patient autonomy and dignity, 
and to commercial issues. [34] WMA recommends that the collection and usage of patient data should 
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require patients to be properly informed, with a clearly defined set of information about how their data 
will be used. Further, WMA recommends that when this is impracticable, there must be a governance 
process that protects patient rights across all future uses of their data. And, a broad consent agreement 
should not be unconditional. These recommendations primarily concern physicians. Nevertheless, they 
could be broadened to other HCSs and integrate patient and citizen concerns. This integrative 
approach can already be spotted in the literature. Ethical, legal and social implications (ELSI) focus on 
topics of consent, disclosure, data sharing, privacy and confidentiality at a population level. [35] 
However, as a complement, in its 2015 report, the Nuffield Council on Bioethics recommended the 
usage of four essential principles - respect for the person, respect for established human rights, 
participation of those with morally relevant interests, and accounting for decisions – that integrate 
bottom-up ethical considerations to biological and health data. [36]  
 
Similar ethical reflections have already been developed when a tension has arisen between clinical 
research for public interest (framed with a utilitarian approach) and individual care (based on a 
deontological framework and patient rights). It was advocated that patients’ values and knowledge 
should also be considered when their data is used. [37] In the case of governance of big biobanks, 
Brownsword proposes to have recourse to a “mini-constitution” that simultaneously protects patients 
from disproportionate claims of public interest, whilst introducing greater flexibility for future 
research. [38] This human-rights-based approach, with greater patient involvement, could be applied 
to all large patient data sets. It is acknowledged that patients and scientific citizens should have an 
increasing role in the management of human genetic and health databases in a democratic society. 
Citizens’ participation would therefore require the development of public programs for health digital 
education, and public spaces for deliberation and citizen consultation. [39].  
 
Whilst it is beyond the scope of this paper to enter into a detailed normative development, we think 
that the approaches presented above, that emphasize the need to involve patients and citizens, provide 
us with a good starting-point for further ethical reflections with regard to the production and use of 
large patient data sets. Our paper is to be read neither in favour of nor against one specific group of 
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stakeholders. Identifying a tension can be positive in cases of complex situations, helping to advance a 
change in perspective.  
 
Limitations and future steps 
The final analysis of this study must be considered with caution, as empirical findings are not directly 
translatable into normative ethics. During the interviews, we could not avoid a gender effect, which 
reflects the actual Swiss situation of fewer women than men in leadership positions. Interviewees were 
also predominantly physicians, as often observed in the healthcare domain. These observations on 
gender and profession may explain the traditional and deontological perspectives of the Swiss HCSs 
regarding patient rights and patient passivity. We did not have access to the patients enrolled in the 
interviewees’ CRGs because of anonymity rules. Patients were thus not interviewed, with the 
exception of one patient organisation representative from the discriminative sample. As a next step, it 
would be paramount to investigate the patient perspective directly, and the evolution of the patient-
physician relationship when confronted with the complexity of the creation of large patient data sets, 
as well as the use and the return of the resulting information. However, it is not always easy to study 
patients, as they can be too focused on specific pathologies or possibly under the influence of for-
profit industrial lobbies. [40] Our findings, showing consequences for the whole of society, argue for 
broad representation from the community in future empirical investigations.  
 
CONCLUSION  
The aim of this research was to gain an in-depth understanding of how those involved in the collection 
and use of patient data - healthcare professionals, regulators and policy makers - were aware of related 
ethical issues. Transferable research findings can be recapitulated as follows: First, a utilitarian 
inclination towards norms and guidelines aiming at facilitating the collection and use of patient data 
appears insufficiently balanced by a duty-oriented deontological approach to patient rights; second, 
HCSs did not assign much importance to patient rights in terms of patient agency and their ability to 
share steering decisions; third, at the societal level, it follows that there is a pre-eminence of experts’ 
role in the governance of large patient data sets at the expense of consumers’ representation. These 
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findings raise ethical questions regarding patient rights, social justice and trust in public institutions 
that might undermine the expected social benefits of data sharing. For these reasons, HCSs should be 
more aware of the identified tension between public interest and patient rights, with further ethical 
guidance being required. Rather than setting patient rights against public interest, new ethical 
approaches would aim to strengthen both concurrently, advancing long-term sustainable cooperation. 
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FIGURE LEGENDS 
Figure 1  
Title: Thematic organisation for in-depth understanding 
 
ADDITIONAL FILES 
Additional file 1 
Title: Definition of clinical registries for the purpose of the qualitative study 
 
This data includes a definition of clinical registries based on the U.S. Agency for Healthcare Research 
and Quality (AHRQ) document, and a matrix summarizing the definition and taxonomy of clinical 
registries [6]. At the time of the interview, this definition was read and the interviewees were asked to 
fill in the matrix to identify their own CRG experience.  
 
Additional file 2 
Title: Literature research strategy for the qualitative research 
 
This file illustrates the ad-hoc literature review which identified an initial framework of ethical 
potential issues to be raised by CRG stakeholders, and helped develop topic guides and prompt cards 
for the semi-structured interviews.  
 
Additional file 3 
Title: Topic guide example for the group “M” making the clinical registries 
 
This data shows an example of the topic guide used for the interview of the group M participants. The 
topic guides for groups A and R had a first part slightly different to fit with their own working 
experience with clinical registries. They are not shown but available on request. 
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